ஜெநெடிக் நோய்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜெநெடிக் நோய்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜெநெடிக் நோய்கள் Today - Breaking & Trending Today

ProMIS Neurosciences Inc.: ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board


(0)
TORONTO and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Rudolph Tanzi, Ph.D, as Chair of the Company s scientific advisory board (SAB). Dr. Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital. ....

New York , United States , Memorial Sloan Kettering Cancer Center , United Kingdom , Cold Spring Harbor Laboratory , San Diego , City Of , Rudy Tanzi , Florence Riford , C Warren Olanow , Sharon Cohen , Neilr Cashman , Eugene Williams , Nicholas Rigopulos , Neil Cashman , Williamc Mobley , Joe Perry , Andre Strydom , David Wishart , Michellel Hastings , Rudolph Tanzi , King College London , Department Of Neuroscience , Research Unit , University Of British Columbia , Royal Institute Of Technology ,

SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform for Non-Viral Gene Therapy

Introducing a mammal-derived genome engineering enzyme for next-generation gene and cell therapy Financing to fund SalioGen’s pipeline in genetic diseases, based on proprietary EDIT ‘gene coding’ platform to advance durable, safe and affordable non-viral gene therapies Financing concurrent with strengthening of board of directors and scientific advisory board BURLINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) SalioGen Therapeutics, a privately held biotechnology company advancing Exact DNA Integration Technology (EDIT) for non-viral gene therapy, today announced that it has closed a $20 million Series A financing. The round was led by PBM Capital, a healthcare-focused investment firm, and included other undisclosed investors. Proceeds from the financing will be used to support the preclinical validation of the Company’s proprietary Exact DNA Integration Technology (EDIT) platform for the development of durable, safe and affordable in vivo gene therapies, i ....

Scientific Advisory Board , Exact Dna Integration Technology , Genetic Diseases , Gene Therapies , Gene Therapy , Integration Technology , Cell Therapy , சரியான டீயெநே ஒருங்கிணைப்பு தொழில்நுட்பம் , ஜெநெடிக் நோய்கள் , கீந் சிகிச்சைகள் , கீந் சிகிச்சை , ஒருங்கிணைப்பு தொழில்நுட்பம் , செல் சிகிச்சை ,